Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06110377
Other study ID # 004
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 30, 2023
Est. completion date April 2, 2025

Study information

Verified date October 2023
Source Clinica Dermatologica Arbache ltda
Contact SAMIR ARBACHE, PhD
Phone 12 981221011
Email samir.arbache@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized clinical trial carried out on 60 Brazilian men, aged 18 to 65, with mild or moderate androgenetic alopecia. Two techniques for administering dutasteride will be compared, injected by syringes or needles or by needling through tattoo machines.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date April 2, 2025
Est. primary completion date April 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy volunteers male patients. - Aged 18 to 65 years. - Patients with male androgenetic alopecia (grades III - V of the Norwood/Hamilton scale) - Commitment not to initiate any other treatment, topical, systemic or intralesional, that interferes with hair growth during the study period. - Patient without systemic treatment for AGA (5 reductase inhibitors) for more than 12 months or without topical treatment for more than 6 months before the start of the study. - Allow the creation of two micro tattoos (maximum size of 1 mm each, resembling a hairy infundibulum) in the area that will be treated, in order to standardize the trichoscopic analysis. - With the aim of photographic standardization, the patient must agree to have their hair cut in a standardized way in the first and last interventions. - Patient about to get his partner pregnant. - Patient must refrain from donating blood during the investigation and up to 6 months after the last intervention, - Patient must abstain from drinking alcoholic beverages, abstain from using inhaled or injectable drugs, abstain from using illicit drugs within 30 days of entering the study, - Patients without a psychiatric diagnosis and who behave appropriately during the interview, - Signs of good hygiene and that have the ability to keep the areas undergoing treatment clean until they heal, - Patients who understand and speak Portuguese, - Patients with realistic expectations regarding the final benefits of treatment, - Needle phobia, - Independent patient, eliminating the need for tutoring or legal representative, - Absence of chronic viral diseases, for example HIV, hepatitis B or hepatitis C, - Absence of other skin diseases, for example lichen planus, psoriasis, Crohn's disease or ulcerative colitis, - Absence of immunosuppression, for example: lymphoma, transplant therapy, chronic corticosteroid use, Wiskott-Aldrich Syndrome or uncontrolled malignancy, - Patients/participants with previously known allergies or those detected during the interventions (anesthetics, topical antibiotics or other medications used in the trials), - Absence of clinically significant cardiovascular disease (e.g. previous myocardial infarction), absence of coagulopathy or use of anticoagulants, absence of neurological disease (e.g. stroke, cerebral ischemia), absence of renal, hepatic or endocrine disease (e.g. example, diabetes). - Patient/participant with medical conditions not mentioned, which in the investigator's view, prohibit participation in the study. - Signature of informed consent Exclusion Criteria: - Detection during the test of allergy to the medicines used (anesthetics, topical antibiotics or other medicines used in the tests), - Breach of protocol, inappropriate conduct that compromises participant safety or interferes with the interpretation of study results, - Any illness or condition, which in the judgment of the investigators, interferes with the participant's ability to complete or terminate the investigation.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)
After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
MMP (INJECTIONS WITH A TATTOO MACHINE)
After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.

Locations

Country Name City State
Brazil Clinica Dermatologica Arbache São José dos Campos São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Clinica Dermatologica Arbache ltda

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary HAIR DENSITY analysis of hair density (number of follicles) per square centimeter using Trichoscale software (fotofinder) and clinical photographs. 1 year
Primary HAIR THICKNESS measurement of the thickness of hair shafts using Trichoscale software (fotofinder) 1 year
Secondary Sexual effects Assessment of sexual adverse effects (sexual impotence or decreased libido) through Likert questionnaire: The answer will be dichotomous, did you feel any sexual effects (impotence or decreased libido during your treatment? Yes or no? 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05611593 - Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia Phase 1
Completed NCT03676400 - Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia N/A
Recruiting NCT05938569 - Computer-Assisted Hair Restoration Study Using ARTAS System N/A
Not yet recruiting NCT06326359 - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia N/A
Recruiting NCT05426629 - Hydraderm for Androgenic Alopecia Phase 4
Recruiting NCT05369481 - Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia N/A
Recruiting NCT05827991 - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia N/A
Not yet recruiting NCT06292533 - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study N/A
Completed NCT02824380 - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Phase 1
Completed NCT06112782 - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality N/A
Completed NCT02594046 - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia N/A
Recruiting NCT05435625 - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia N/A
Completed NCT05450861 - Effect of the Composition From Fish on Promoting Hair Growth N/A
Completed NCT03506503 - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia N/A
Completed NCT03467412 - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Phase 2
Completed NCT01852487 - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia N/A
Not yet recruiting NCT03474718 - Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Early Phase 1
Active, not recruiting NCT02914587 - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study N/A
Completed NCT04341363 - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT04450602 - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss N/A